Can Sclerotherapy Cause Blood Clots?

Sclerotherapy can cause blood clots, though the risk is low for most patients. In a study tracking over a thousand treated legs, deep vein thrombosis occurred in about 1.5% of cases, and only two of those were symptomatic. The procedure works by deliberately damaging the inner lining of unwanted veins, which triggers a clotting and scarring process that shuts them down. Occasionally, that clotting extends where it shouldn’t, and the line between expected treatment effect and unwanted complication is more nuanced than most patients realize.

How Often Deep Vein Thrombosis Occurs After Sclerotherapy

The largest single-center study tracking DVT after foam sclerotherapy followed 1,000 legs and detected 17 deep vein thromboses, a rate of 1.5% overall. Almost all of those clots occurred in legs treated for larger trunk veins rather than smaller spider veins or reticular veins, with the DVT rate climbing to about 2.4% in that subgroup. Of those 17 clots, only two caused noticeable symptoms. Most were small, sitting right at the junction where a surface vein meets a deep vein, and were caught on routine ultrasound scans rather than by patient complaints.¹

The amount of foam injected turned out to be the strongest predictor. When ten or more milliliters of foam were used in a single session, the odds of DVT jumped roughly fivefold compared to smaller volumes.¹ This dose-response relationship is consistent with broader reviews that link higher foam volumes to both local and distant clotting problems.²

Tibial vein clots, which form in the smaller deep veins of the calf, are another subtype that shows up after foam treatment. A case series found that when these clots did occur, the majority resolved completely within about five weeks. None progressed to pulmonary embolism, and most patients’ symptoms cleared regardless of whether they were managed with blood thinners or observation alone.³

Deep Vein Sclerosis Is Not the Same as a Blood Clot

Here is where the picture gets more interesting than a simple yes-or-no. Sclerotherapy is designed to damage the vein wall and cause it to scar shut, a process called fibrosclerosis. When sclerosant accidentally reaches a deep vein, it can trigger the same scarring reaction there. Researchers have argued that this “deep vein sclerosis” is a fundamentally different process from a spontaneous DVT. In a typical blood clot, a thrombus forms within an otherwise healthy vein, often driven by sluggish blood flow or a clotting disorder. In deep vein sclerosis, the vein wall itself has been chemically injured and is undergoing the same fibrotic shutdown that was intended for the surface vein.⁴

This distinction matters practically because deep vein sclerosis may not carry the same risks as a classic DVT. A traditional clot can break loose and travel to the lungs. A sclerotic segment, which is essentially a chemically burned vein wall in the process of scarring, behaves differently on ultrasound and produces different patterns of D-dimer elevation. That said, telling the two apart on a scan is not always straightforward, and many clinicians treat any deep vein occlusion found after sclerotherapy with the same caution they would apply to a DVT.

Pulmonary Embolism After Sclerotherapy

Pulmonary embolism is the complication that worries patients and clinicians most, and it does happen, though rarely. In a large randomized trial comparing laser ablation, surgery, and foam sclerotherapy for varicose veins, one patient in the foam group developed a pulmonary embolism, while one patient in the surgery group developed a DVT. No other major complications were recorded across the trial arms.⁵

Fatal pulmonary embolism is exceptionally rare but has been documented. One reported case involved a patient who had foam sclerotherapy combined with extensive phlebectomy. That patient had several compounding risk factors: unsuspected widespread artery disease, obesity, and use of an oral contraceptive. The authors also noted that a beta-blocker the patient was taking may have worsened the outcome by masking early warning signs like a racing heart.⁶ Based on broader data, that same report estimated real-world thromboembolic complication rates of roughly 2.4% to 4.7% across ambulatory phlebology practices, higher than the rates typically seen in controlled study settings.

A review of sclerotherapy-related pulmonary embolism cases found that symptoms ranged from none at all to severe oxygen deprivation and cardiac arrest. Onset varied from immediately after the procedure to as late as ten days afterward. In over half the cases reviewed, both lungs were affected.⁷ The takeaway is that while pulmonary embolism after sclerotherapy is uncommon, it does not always announce itself loudly. Breathlessness, chest tightness, or a rapid heart rate in the days following treatment deserve urgent attention.

Stroke and Other Neurological Events

Blood clots traveling to the brain represent one of the more alarming possibilities, and they appear linked to a specific anatomical quirk. About a quarter of the general population has a patent foramen ovale, a small opening between the left and right sides of the heart that normally closes shortly after birth but sometimes doesn’t. In a person with this opening, tiny bubbles or clot fragments in the venous bloodstream can cross into the arterial system and reach the brain.

There are documented cases of ischemic stroke following foam sclerotherapy in patients who turned out to have a patent foramen ovale. Neurological symptoms like transient visual disturbances and brief episodes of confusion had already been reported in the literature, but confirmed stroke added a more serious dimension to the risk profile.⁸ Foam sclerotherapy, by its nature, introduces gas bubbles into the venous system. In most people those bubbles are filtered by the lungs. In someone with a right-to-left cardiac shunt, the bubbles bypass the lung filter entirely.

Vision loss is another rare but devastating neurological complication. A case of progressive ophthalmic artery occlusion leading to irreversible blindness was reported in a pediatric patient after foamed polidocanol injection, underscoring that embolic events can affect virtually any arterial territory once material crosses into the systemic circulation.⁹ Whether routine screening for patent foramen ovale before foam sclerotherapy is warranted remains debated, but many practitioners now ask about a history of migraine with aura (which correlates with the defect) as an informal screen.

What Makes Some Patients Higher Risk

Several factors appear to push the risk of clotting after sclerotherapy higher than the baseline rates:

Foam volume: As already noted, using ten or more milliliters of foam in a single session roughly quadrupled the odds of DVT in the largest tracking study.
Obesity: Excess body weight is a recognized independent risk factor for venous thromboembolism, and it showed up as a contributing factor in the fatal PE case described earlier.
Hormonal medications: Oral contraceptives and hormone replacement therapy increase baseline clotting risk. Their combination with a procedure that itself provokes clotting creates a compounding effect.
Prior DVT or PE: Patients with a history of deep vein thrombosis carry an elevated risk of recurrence with any procedure that disrupts venous flow.
Patent foramen ovale: This heart defect opens a route for embolic material to reach the arterial side, raising the stakes for neurological events specifically.

People with inherited clotting disorders might assume sclerotherapy is off the table for them, but the evidence is more reassuring than you’d expect. A controlled study followed 105 patients with the three most common forms of thrombophilia through sclerotherapy. All received blood-thinner prophylaxis alongside their treatment. None developed symptomatic DVT or pulmonary embolism, and none had DVT detected on follow-up ultrasound.¹⁰ The study suggests that with proper precautions, even patients carrying a genetic clotting tendency can undergo sclerotherapy safely, though this clearly requires close coordination between the treating physician and the patient.

Reducing the Risk

Compression stockings are the most commonly recommended safeguard after sclerotherapy. Clinical guidelines from multiple professional societies suggest starting compression immediately after treatment to improve outcomes.¹¹ However, a systematic review found that the evidence behind specific compression protocols is thin. Questions about the ideal stocking type, pressure class, and how long to wear them remain unanswered.¹² And at least one randomized trial found no measurable difference in side effects, satisfaction, or quality of life between patients who wore compression and those who did not.¹³

For higher-risk patients, pharmacological thromboprophylaxis enters the conversation. A study of 54 patients who had previously suffered DVT or pulmonary embolism looked at outcomes when foam sclerotherapy was combined with three days of low-molecular-weight heparin injections and three weeks of compression stockings. None developed DVT or symptomatic PE. Localized phlebitis, a milder inflammatory reaction in surface veins, occurred in under 3% of treatments.¹⁴

Beyond patient-level precautions, technique modifications can also reduce risk. Suggested strategies include using lower foam volumes, elevating the leg before or after injection, using low-silicone syringes, using non-air-based foam formulations (carbon dioxide and oxygen mixtures absorb into blood faster than room air), and keeping the patient still during and just after injection.¹⁵ Some practitioners also manually compress the junction where the treated surface vein meets the deep venous system, aiming to prevent sclerosant from flowing inward.

How Sclerotherapy Compares to Other Varicose Vein Treatments

If clotting risk is a concern, it’s worth knowing how foam sclerotherapy stacks up against alternatives. The CLASS trial, one of the larger head-to-head comparisons, found that both laser ablation and surgical stripping produced better outcomes than foam sclerotherapy for symptomatic varicose veins.¹⁶ In the randomized trial mentioned earlier that compared all three approaches alongside radiofrequency ablation, the overall rate of major complications was extremely low across the board, with one PE after foam sclerotherapy and one DVT after surgery.⁵

No treatment is clot-proof. Thermal ablation techniques (laser and radiofrequency) can also extend heat damage into deep veins, and surgical stripping involves its own set of anesthesia-related and wound-related risks. Foam sclerotherapy retains advantages that keep it popular: it requires no anesthesia, can be done in an office visit, and is the cheapest option. For smaller spider veins and reticular veins, where the alternatives are less practical, it remains the standard treatment. The clotting risk tends to be concentrated in the treatment of larger trunk veins, where alternatives exist and the decision about approach deserves a more careful risk-benefit conversation.

Clotting Risks in Non-Venous Sclerotherapy

Sclerotherapy isn’t used only for varicose veins. It’s also a common treatment for vascular malformations, clusters of abnormally formed blood vessels that are present from birth. The clotting dynamics here are different and sometimes more dangerous. Slow-flow vascular malformations are prone to a condition called localized intravascular coagulopathy, where blood inside the malformation tends to clot and bleed at the same time. Sclerotherapy has been identified as a potential trigger for worsening this coagulopathy, pushing it toward a body-wide clotting crisis known as disseminated intravascular coagulopathy. In at least one documented case, a patient on preventive blood thinners still developed pulmonary emboli after sclerotherapy for a vascular malformation.¹⁷

Research into how clotting markers change after sclerotherapy of venous malformations is ongoing, with studies tracking D-dimer and other indicators to predict which patients are most vulnerable and whether treatment response can be gauged from these blood markers.¹⁸ The bottom line for patients with vascular malformations is that the clotting risk profile is meaningfully different from that of someone having spider veins treated, and it requires specialized hematologic monitoring.

Not All Sclerosants Carry the Same Risk

The chemical agent used matters. An analysis of the World Health Organization’s global pharmacovigilance database found that the safety profiles of different sclerosing agents differ significantly, and those differences should inform how clinicians weigh risks and benefits for individual patients.¹⁹ A separate analysis of adverse events reported to the U.S. FDA confirmed that while the most common complaints involved local symptoms like pain and skin changes, serious events including death were associated with specific individual sclerosants.²⁰

The most widely used agents include sodium tetradecyl sulfate and polidocanol. Both can be used as liquids or whipped into foam. Foam formulations are more potent per milliliter because the foam displaces blood from the vein and keeps the sclerosant in contact with the vessel wall longer, but that same potency brings more systemic exposure and, as the volume data show, a higher risk of deep vein involvement. Choosing between agents and between liquid and foam formulations is part of how experienced practitioners tailor the procedure to the patient’s anatomy and risk profile.

Malpractice Claims and Informed Consent

The legal landscape around sclerotherapy complications offers a revealing window into where things go wrong in practice. A review of venous disease malpractice litigation found that post-procedure complications accounted for the vast majority of claims. Among varicose vein cases specifically, about 15% involved DVT or pulmonary embolism as the alleged complication. Foam sclerotherapy was the second most commonly named procedure in these lawsuits, trailing only stab phlebectomy. A quarter of all claims cited lack of informed consent as a contributing issue.²¹

A separate analysis of medical liability claims in Europe found that deep vein injury and insufficient communication between doctor and patient together accounted for a substantial share of accepted claims. Among claims that were upheld, deep vein injury was one of the most common bases for a finding that the physician had failed to provide expected care.²² The pattern across both datasets is consistent: it’s not just the complication itself that generates legal exposure, but the failure to warn the patient about it beforehand. If you’re considering sclerotherapy, the informed consent discussion should explicitly address DVT and PE risk, and you should feel comfortable asking about it if it doesn’t come up.